Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Arena begins phase II trial of etrasimod for moderate to severe alopecia areata

Sep. 2, 2020

Innovent opens phase I study in China with IBI-112 for autoimmune diseases

Sep. 2, 2020

FDA approves Winlevi for acne

Aug. 27, 2020

Novartis details development of best-in-class LTA4 hydrolase inhibitor LYS-006

Aug. 27, 2020

Jiangsu Hansoh Pharmaceutical Group, Shanghai Hansoh Biomedical patent JAK-2, TYK2 inhibitors

Aug. 14, 2020

Phase IIa study of KY-1005 in atopic dermatitis meets primary endpoints

Aug. 11, 2020

Cosentyx approved in the E.U. for pediatric psoriasis

Aug. 3, 2020

Lilly discovers interleukin-17 receptor A antagonists

July 30, 2020

Krystal begins phase III study of beremagene geperpavec for dystrophic epidermolysis bullosa

July 29, 2020

UCB begins first-in-human evaluation of UCB-8600

July 23, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...